Benitec Biopharm Stock Price, News & Analysis

Benitec Biopharma (NASDAQ: BNTC) has released its Q2 2025 financial results and provided updates on its BB-301 Phase 1b/2a clinical trial for Oculopharyngeal Muscular Dystrophy (OPMD). The fifth subject was safely treated in February 2025, with interim results showing durable, clinically meaningful improvements in swallowing function for the first subjects treated.

Financial highlights for Q2 2025 include:

• Revenue: $0.0 million
• Total expenses: $8.6 million (up from $6.9 million in Q2 2024)
• Net loss: $7.4 million, or ($0.33) per share
• Cash position: $78.3 million as of December 31, 2024

The company plans to begin treating a second cohort with a higher dose of BB-301 later in the year. An interim clinical study update will be presented at the 2025 Muscular Dystrophy Association Conference on March 19, 2025.

Benitec Biopharma (NASDAQ: BNTC) announced the acceptance of a late-breaking oral abstract for their BB-301 Phase 1b/2a Clinical Treatment Study at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference. The presentation, scheduled for March 19, 2025, will provide interim updates on the first three subjects treated with BB-301 for Oculopharyngeal Muscular Dystrophy (OPMD) with moderate dysphagia.

The company previously reported in October 2024 that the first two subjects showed durable, clinically meaningful improvements in swallowing function following BB-301 treatment. The therapy, based on Benitec's proprietary 'Silence and Replace' DNA-directed RNA interference platform, aims to address dysphagia, a severe, life-threatening complication of OPMD. Additional clinical updates for enrolled subjects are planned for Q4 2025.

Benitec Biopharma (NASDAQ: BNTC), a clinical-stage biotechnology company specializing in gene therapy and novel genetic medicines based on their proprietary 'Silence and Replace' DNA-directed RNA interference (ddRNAi) platform, has announced their participation in three upcoming conferences.

The company will attend the Muscular Dystrophy Association Gene Therapy Summit in Tucson, AZ from January 28-30, 2025, followed by the Guggenheim SMID Cap Biotech Conference in New York, NY on February 5, 2025, which will feature one-on-one meetings. Additionally, Benitec will present at the virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025, at 2:00 PM EST, offering both a presentation and one-on-one meeting opportunities. The Oppenheimer presentation will be available via live webcast.

Benitec Biopharma (NASDAQ: BNTC), a clinical-stage biotechnology company focused on gene therapy and developing genetic medicines using their proprietary 'Silence and Replace' DNA-directed RNA interference platform, has announced their participation in two upcoming investor conferences in December 2024.

The company will participate in the Piper Sandler Annual Healthcare Conference on December 4, 2024, at 12:00 PM EST in New York, featuring a fireside discussion and one-on-one meetings. Additionally, they will attend the Oppenheimer Movers in Rare Disease Summit on December 12, 2024, from 9:50-10:40 AM EST in New York, participating in a panel discussion and one-on-one meetings.

Benitec Biopharma (NASDAQ: BNTC) has released its Q1 2025 financial results and operational updates. The company reported positive interim clinical study data for BB-301 in treating Oculopharyngeal Muscular Dystrophy (OPMD). The first subject showed 35-40% improvement in dysphagic symptoms at 270 days, while the second subject achieved a clinically normal swallowing profile at 180 days. A third subject was treated in October 2024, with a fourth expected in December.

Financial results show no revenue for Q1 2025, with total expenses of $5.8 million. The company reported a net loss of $5.1 million ($0.48 per share) and held $67.8 million in cash as of September 30, 2024.

Benitec Biopharma (NASDAQ: BNTC), a clinical-stage biotechnology company focused on gene therapy and developing genetic medicines using their proprietary 'Silence and Replace' DNA-directed RNA interference (ddRNAi) platform, has announced their participation in the Guggenheim Securities Healthcare Conference. CEO Jerel A. Banks, M.D., Ph.D., will present at the conference on November 11, 2024, at 2:30 PM in Boston. The presentation will be conducted in a fireside chat format with opportunities for one-on-one meetings, and will be available via live webcast.

Benitec Biopharma Inc. (NASDAQ: BNTC) has announced updated investor webcast information for their BB-301 Phase 1b/2a Clinical Study update. The webcast is scheduled for October 14th at 8:30 am EDT, replacing the previously announced conference call information from October 12th.

The live webcast will feature a presentation of interim clinical study data, including insights from management and Dr. Emily Plowman, Professor at The Ohio State University College of Medicine. Investors can access the webcast through a provided link, and a replay along with presentation slides will be available on the company's website afterward.

Benitec Biopharma is a clinical-stage biotechnology company focused on developing novel genetic medicines using their proprietary 'Silence and Replace' DNA-directed RNA interference (ddRNAi) platform.

Benitec Biopharma (NASDAQ: BNTC) reported positive interim data from its Phase 1b/2a study of BB-301 for Oculopharyngeal Muscular Dystrophy (OPMD). Two subjects treated with the low-dose BB-301 showed durable, clinically meaningful improvements in swallowing at 9 and 6 months post-treatment, respectively.

Key findings include:

• No Significant Adverse Events reported
• Subject 1 experienced a 35% reduction in Sydney Swallow Questionnaire (SSQ) Total Score and significant improvements in videofluoroscopic swallowing study (VFSS) assessments
• Subject 2 achieved an 89% reduction in SSQ Total Score, reaching a clinically normal swallowing profile
• Strong correlation between SSQ scores and VFSS Total Pharyngeal Residue results

These results represent the first reported successful improvements in swallow function using a novel gene therapy for OPMD. Benitec plans to treat a third subject with the low dose and enroll additional subjects at higher doses in 2025.

Benitec Biopharma Inc. (NASDAQ: BNTC) has released its full year 2024 financial results and operational update. Key highlights include:

- Positive 90-day and 180-day interim clinical trial data for the first OPMD subject dosed with low-dose BB-301

- Second subject dosed in February 2024, third expected in Q4 2024

- Closed $40.0 million private placement financing in April, extending cash runway through 2025

- Total revenues were $0 for FY2024, compared to $75,000 in FY2023

- Total expenses increased to $22.5 million in FY2024 from $19.2 million in FY2023

- Net loss of $22.4 million, or $5.51 per share, compared to $19.6 million, or $14.12 per share in FY2023

- Cash and cash equivalents of $50.9 million as of June 30, 2024